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E-mail address: fangy2@corning.com (Y. Fang).Ligand-directed functional selectivity has stimulated much interest in the molecular delineation of
drug pharmacology and the process of drug discovery. Here we describe the development of a label-
free optical biosensor with microﬂuidics for whole cell sensing. The microﬂuidics controls the dura-
tion of agonist exposure and of the functional recovery of activated protease activated receptor-1
(PAR1). The biosensor manifests that the persistency of PAR1 signaling is dependent on the agonists,
which, in turn, affects the receptor resensitization process. This study demonstrates a new means to
differentiate ligand-directed functional selectivity on trafﬁcking of receptors.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Ligand-directed functional selectivity or biased agonism is orig-
inated from the observations that many G protein-coupled recep-
tor (GPCR) ligands exhibit different abilities to produce certain
but not all receptor behaviours [1–3]. This is illustrated by different
proteases that elicit distinct responses through the activation of
protease activated receptor-1 (PAR1, thrombin receptor) [4].
Thrombin is the main coagulation protease that can proteolytically
activate PAR1, resulting in pro-inﬂammatory responses and disrup-
tion of endothelial barrier [5]. Activated protein C, also an anti-
coagulant protease, binds to its co-factor endothelial protein C
receptor, which, in turn, cleaves and activates PAR1, leading to
anti-inﬂammatory responses and stabilization of endothelial
barrier [6]. Synthetic peptide agonists (PAR activating peptides,
PAR-APs) including SFLLR that mimic the N-terminus tethered li-
gand domain can activate PAR1 independently of proteolysis [7].
The PAR-AP agonists were found to favour Gaq activation over
Ga12/13, opposite to thrombin, in a human endothelial cell line
[8]. The pathway selective activities of PAR1 agonists add new rev-chemical Societies. Published by E
n; GPCR, G protein-coupled
AP, PAR activating peptide;enue in elucidating PAR1 signaling and functions in various tissues
and cell types. However, biased agonism of PAR1, in general GPCR
ligands, is mostly measured via various signaling molecules [9];
and in most cases the signaling and cell type-speciﬁc responses
elicited by different PAR1 agonists remain poorly understood [4].
Resonant waveguide grating (RWG) biosensor is a nano-grating
waveguide-based optical biosensor [10] that has attracted much
interest in the molecular delineation of receptor biology and ligand
pharmacology [11–14], because it enables non-invasive, sensitive
and integrative measures of cell signaling based on stimulus-in-
duced dynamic mass redistribution (DMR) in living cells [15–17].
However, in typical biosensor cellular assays a ligand is introduced
using a pipetting system and cells are continuously exposed to the
ligand, thus creating a static and sustained stimulation scheme [10].
Such an assay format may mask certain biased activities of various
ligands. To overcome this, we here describe the development of a
microﬂuidic RWG biosensor system and its uses for detecting li-
gand-directed functional selectivity on trafﬁcking of PAR1.2. Materials and methods
2.1. Materials
Thrombin and cycloheximide were obtained from Sigma Chem-
ical Co. (St. Louis, MO, USA). Argatroban was obtained from Tocrislsevier B.V. All rights reserved.
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(King of Prussia, PA, USA). Epic 384-well biosensor microplates
and inserts were obtained from Corning Inc. (Corning, NY, USA).
Poly-dimethylsiloxane (PDMS) was obtained from Dow Chemical
(Midland, MI, USA). Live/Dead staining kits and sulforhodamine B
were from Invitrogen (Carlsbad, CA, USA).
2.2. Cell culture
Human lung adenocarcinoma epithelial cell line A549 was ob-
tained from American Type Cell Culture. The cells were cultured
in the cell culture medium (Dulbecco’s modiﬁed Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS) and
100 lg/ml penicillin and streptomycin) at 37 C under air/5% CO2.
2.3. Fabrication of microﬂuidic biosensor devices
Soft lithography was used to fabricate the microﬂuidic device
using PDMS (poly-dimethylsiloxane) replicas [18]. Brieﬂy,
features on chrome mask were transferred onto silicon wafers
using standard photolithographic process. The photoresist-de-
ﬁned silicon wafers were then anisotropically etched to a desired
depth in a multiplex inductively coupled plasma etching system
(Surface Technology Systems, Newport, NJ, USA). After photoresist
removal and coating using trichloro(1H,1H,2H,2H-perﬂuoro-
octyl)silane, a PDMS pre-polymer solution containing a mixture
of PDMS oligomers and a reticular agent (10:1 mass ratio)
(Sylgard 184 Kit, Dow Corning Corp., Midland, MI, USA) was cast
onto the etched silicon wafers and cured at room temperature for
about 24 h to minimize shrinkage after curing. Next, the PDMS
replicas were carefully peeled away from the wafers. Finally,
after punching inlet and outlet holes, the PDMS replica was
aligned and reversibly bonded onto the top of Epic biosensor
inserts.
For cell culture, the device, tubing (Tygon S-54-HL, Saint-Gob-
ain Performance Plastics, Akron, OH, USA) and syringes (500 ll,
gas tight 1700 series, Hamilton, Reno, NV, USA) were ﬁrst sani-
tized with 70% ethanol. The microﬂuidic chambers were then
ﬁlled with the cell culture medium. After cell seeding and
sequential 4 h incubation, tubings were plugged into the micro-
chamber inlets and were connected to syringes that were con-
nected to a syringe pump (Model: SP230IW; World Precision
Instruments, Sarasota, FL, USA). Afterwards, the cells were cul-
tured overnight at 37 C under air/5% CO2 and perfusion of the
cell culture medium at a ﬂow rate of 5 ll/h.
2.4. DMR assays under static and sustained stimulation condition
using Epic system
Epic system (Corning Inc.) is a wavelength interrogation reader
system tailored for RWG biosensors in microtiter plates [10,11].
The detector uses integrated ﬁber optics to record the kinetics of
cellular responses with a time interval of 15 s. Twenty thousand
cells per well were directly seeded and cultured overnight before
assays. After washed twice, the cells were maintained with the as-
say vehicle (HBSS; 1 Hanks’ balanced salt solution, 20 mM Hepes,
pH 7.1) and further incubated inside the system for 1 h. After-
wards, a 2-min baseline was ﬁrst established. Compound solutions
were then transferred using the onboard liquid handler, and the
cellular responses were recorded. Here compounds remained in
the wells once added, and the cells were exposed to the com-
pound(s) throughout the assays, thus creating a static and persis-
tent stimulation condition. Further, since cells are sensitive to
environmental changes, it would be difﬁcult to completely replace
the compound solution using conventional pipetting.2.5. DMR assays under perfusion conditions using a RWG imager
system
We recently developed a whole microplate RWG biosensor im-
ager system [19]. For DMR assays under perfusion conditions, the
imager was modiﬁed to increase spatial solution as well as to
accommodate the reduced footprint of the microﬂuidic biosensor
device. Speciﬁcally, a tunable light source is passed through a pola-
rizer to generate a polarized light, which is then expanded through
optical lens and mirrors to simultaneously illuminate at a normal
incident angle all biosensors within the microﬂuidic device. The
tunable light source linearly scans the wavelength range from
826 to 838 nm in every 3 s, such that the biosensor array is illumi-
nated and synchronously imaged by a 1400  1024 pixel comple-
mentary metal oxide semiconductor camera (Dalsa Inc., Ontario,
Canada). The spectral images are processed online to extract the
resonant wavelengths. In order to minimize assay variability as
well as the impact of time lag across the biosensor, cells only lo-
cated within the central area of a biosensor (0.2  2 mm) were
sampled to generate an averaged response.
2.6. Quantitative real-time PCR
Total RNA was extracted from A549 cells using RNeasy mini kit
(Qiagen, Cat#74104). To eliminate genomic DNA contamination,
on-column DNase digestion was performed using RNase-free
DNase set (Qiagen, Cat#79254). The concentration and quality of
total RNA were determined using Nanodrop 8000 (Thermo Scien-
tiﬁc). Customized PCR-array plates for 352 GPCR genes and re-
agents were ordered from SABiosciences. About 1 lg total RNA
was used for each 96-well PCR-array. The PCR-array was per-
formed on an ABI 7300 Real-Time PCR System following manufac-
turer instructions.
2.7. Fluorescence microscopy
Live/Dear cell staining was carried out using the protocol rec-
ommended by the supplier. A Zeiss Axioplan ﬂuorescence micro-
scope was used to collect all ﬂuorescence and light images.
3. Results
3.1. Prototyping microﬂuidic biosensor system
We ﬁrst developed a prototype of microﬂuidic RWG biosensor
system (Fig. 1). The microﬂuidic device consists of a 4  8 array
of biosensors, each biosensor having a dimension of 2 mm  2 mm
and the array having a footprint that is compatible to a standard
384-well microplate. The device also contains a 4  4 array of
microﬂuidic chambers, each having three inlets and one outlet,
and the microchamber array covering a 4  8 array of biosensors
so only one biosensor is centered in each microchamber and its
adjacent biosensor is sacriﬁced. Syringe pumps are connected to
the inlets to deliver solutions at a controlled ﬂow rate. The distance
from an inlet to the outlet is 9 mm, the central width of the cham-
ber 5 mm, and the height of the microchannel 200 lm. The total
volume required to ﬁll up a chamber is 6 ll. To minimize the im-
pact of shear force on cell biology, a ﬂow rate of 1–5 ll/min was
used. Given the microﬂuidic conﬁgurations we estimated that the
shear force is <2.5  102 dyn/cm2, well below those commonly
used to trigger activation of certain signaling cascades such as
extracellular signal-regulated kinases and N-terminal Jun kinase
in certain cells [20,21].
To monitor cellular responses, we also developed a RWG imager
that is capable of simultaneously imaging all biosensors within an
RWG biosensor
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Fig. 1. A microﬂuidic RWG biosensor array for whole cell sensing. (a) A false coloured image of the biosensor array recorded using a digital camera by titling the biosensor
plate under white light until a resonance condition was achieved. Different colours were seen due to difference in environment surrounding each sensor. Biosensors within
the microﬂuidic device were pre-ﬁlled with the cell medium solution. (b) Schematic of a microﬂuidic chamber (open view). The false coloured image is an actual resonant
image of a biosensor obtained using the RWG imager. The biosensors were covered with a monolayer of A549 cells via overnight culture. The white box indicates the location
at which the cellular responses were monitored. (c) Fluorescence image of cells on the biosensor in (b) after Live/Dead staining. The green ﬂuorescence indicates cells alive,
and the red died cells. (d) The ﬂuorescence intensity of the sampled area as a function of time. Here a 2 ll ﬂuorescent dye solution (10 lg/ml sulforhodamine B) was perfused
between the two perfusion steps with the assay buffer. The ﬂow rate for all three steps was the same (2 lg/min).
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resolution of 3 s. Fig. 1b showed a resonant wavelength image of a
biosensor, wherein the biosensor was covered with a monolayer of
A549 cells (Fig. 1c). Cell viability testing using the Live/Dead stain-
ing protocol suggests that almost all cells were viable.
To characterize the microﬂuidics device, a microchamber hav-
ing no cells was sequentially perfused with the assay buffer, a ﬂuo-
rescent dye solution (10 lg/ml sulforhodamine B) for 1 min, and
the assay buffer again, all at a constant ﬂow rate of 2 ll/min. This
created a 2 mm wide dye solution sandwiched between the two
buffer solutions. The kinetics of the dye solution passing through
the device was examined using ﬂuorescence microscopy. The ﬂuo-
rescence intensity at the sampled area, as indicated by the white
box (0.2  2 mm) in Fig. 1b, was recorded 1 min after the dye injec-
tion (Fig. 1d). Results showed that at t0 (49 s) the ﬂuorescence
intensity started rising, indicating that the dye molecules reachedthe area. At t1 (57 s) the ﬂuorescence intensity reached the maxi-
mum, suggesting that the rising time to reach the injected concen-
tration is <8 s. At t2 (110 s) the ﬂuorescence intensity started
decaying, suggesting that the second buffer started to deplete the
dye solution in the sampled area. At t3 (118 s) the ﬂuorescence
intensity was back to the baseline, suggesting that the rinsing time
to completely deplete the ﬂuorescent molecules at the sampled
area is <8 s. Narrowing down the sampled area can further improve
the accuracy of measurements. Nonetheless, these results suggest
that the microﬂuidic system is effective to control the duration
of agonist stimulation and receptor recovery.
3.2. mRNA expression of PARs in A549
Quantitative real time PCR was used to examine expression of
PARs in A549. Results showed that A549 expresses mRNA of
V. Goral et al. / FEBS Letters 585 (2011) 1054–1060 1057PAR1, PAR2 and PAR3, whose threshold cycle (Ct) value was found to
be 22, 22, and 24, respectively. No mRNA was detected for PAR4.
The Ct values were 21 and 15 for two control genes, hypoxanthine
phosphoribosyltransferase 1 and b-actin, respectively.
3.3. DMR characteristics of PAR1 activation
Both thrombin and SFLLR were used to activate the PAR1 un-
der both static and perfusion conditions. Results showed that un-
der both conditions SFLLR resulted in a dose dependent DMR
signal, which shares almost identical DMR characteristics
(Fig. 2a) and EC50 value (4.1 ± 0.4 lM, n = 3 and 3.9 ± 0.6 lM,
n = 3 for static and perfusion conditions, respectively). Similar re-
sults were obtained for thrombin, whose EC50 values were identi-
cal (0.60 ± 0.14 unit/ml) under both conditions (Fig. 2b and c).
Perfusion with 10 unit/ml thrombin in the presence of 10 lM arg-
atroban, a thrombin inhibitor, signiﬁcantly suppressed the throm-
bin signal (Fig. 2d). The thrombin DMR in the presence of
argatroban did not contain any immediate rapid rising phase,
suggesting that the bulk index effect is minimal. Further, perfu-
sion with lipid-free and protease-free bovine serum at a high con-
centration (0.025 wt.%) triggered a quite small response largely
due to its bulk index, suggesting that any signal from non-speciﬁc
absorption of proteins (e.g., thrombin and serum), if at all, is min-
imal. Together, these results suggest that A549 expresses func-
tional PAR1 and the perfusion had little effect on PAR1 agonist
induced DMR signals.-3 -2 -1 0 1 2
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Fig. 2. DMR signals of PAR1 agonists. (a) The DMR of A549 cells responding to SFLLR-am
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with thrombin (10 unit/ml) in the absence and the presence of 10 lM argatroban. All er3.4. Desensitization and resensitization of PAR1 signaling under
distinct stimulation conditions
Homologous desensitization is a hallmark of GPCR signaling.
Thus, the cross-desensitization between thrombin and SFLLR was
ﬁrst examined under the static and sustained stimulation condi-
tion using a previously developed DMR desensitization assay
[22]. Results showed that under the static stimulation condition
both SFLLR (10 lM) and thrombin (10 unit/ml), each at a saturating
dose, resulted in a similar positive-DMR that is sustained for at
least 2 h. Further, the 2nd stimulation with SFLLR only slightly al-
tered the 1st thrombin-induced DMR, and the same was observed
for thrombin in the SFLLR-treated cells (Fig. 3a), suggesting that
thrombin and SFLLR cross-desensitized each other. Similar results
were observed when the two perfusion steps between the ﬁrst
and second agonists were performed sequentially (Fig. 3d). These
results suggesting that both agonists activate the same receptor,
PAR1.
Next, we examined DMR patterns of A549 cells upon repeated
stimulations with PAR1 agonists when an additional perfusion with
the assay vehicle was introduced between the ﬁrst and second ago-
nist perfusion. Here the cells were ﬁrst perfused with the ﬁrst ago-
nist for 30 min, followed by a perfusion with the assay vehicle for a
given period of time (i.e., recovery time), and then a perfusion with
the second agonist (thrombin). In this way, the receptor resensiti-
zation was allowed by the control of recovery time via the contin-
uous ﬂow of the assay vehicle to deplete the ﬁrst agonist after theb
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Fig. 3. Desensitization and resensitization of PAR1 signaling in A549 cells. (a) SFLLR and thrombin cross-desensitized each other when the cells were repeatedly stimulated
under the static and sustained condition. Here the DMR assays were carried out using Epic system, wherein after the initial 2 min baseline recording, two agonist solutions
(the 1st agonist and the 2nd agonist) were added into the same well having cultured cells in a sequential manner using conventional pipetting, and the two steps were
separated about 1 h. The cellular responses were continuously monitored throughout the assays. (b) DMR signals of cells responding to repeated stimulations when an
additional perfusion with the assay vehicle was introduced between the 1st (5 unit/ml thrombin, or 10 lM SFLLR) and 2nd agonist (10 unit/ml thrombin) stimulation. Each
step was continuous for 30 min. (c) The amplitudes of the 2nd thrombin induced DMR as a function of the doses of the 1st thrombin. The recovery time between the two
stimulations was set to be 30 min. (d) The amplitudes of the 2nd thrombin induced DMR as a function of the recovery time. Thrombin was at 10 unit/ml thrombin, and SFLLR
at 10 lM. The agonist responses of the assay vehicle-treated cells were used as positive controls. Similar protocol was used for obtaining (b–d). Brieﬂy, the cell layer was
sequentially perfused with (1) the assay buffer for 10 min to achieve a baseline, (2) the 1st agonist (thrombin or SFLLR) for 30 min to result in the ﬁrst stimulation, (3) the
assay buffer for a speciﬁc period of time to allow the functional recovery of the activated PAR1, and (4) ﬁnally the 2nd agonist (thrombin) for 30 min to study the
resensitization of the activated PAR1. All error bars represented the standard deviation of at least three replicates.
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activation was measured based on the second thrombin induced
DMR. Results showed that when the recovery time was set to be
30 min, removal of thrombin (5 unit/ml) caused the cells respond
to the second thrombin stimulation with a small DMR signal
(Fig. 3b). Conversely, removal of SFLLR (10 lM) caused the cells re-
spond to the second thrombin with a signiﬁcant DMR (Fig. 3b). Fur-
ther, the higher concentration the ﬁrst thrombin the smaller the
second thrombin-induced DMR is (Fig. 3c). Lastly, the longer recov-
ery time the greater response induced by the second thrombin is,
and the recovery of functional PAR1 was much faster in the
SFLLR-activated cells than the thrombin-activated cells (Fig. 3d).
These results suggest that PAR1 resensitization is dependent on
three factors: (1) types of PAR1 agonists; (2) doses of PAR1 ago-
nists; and (3) the recovery time.
Interestingly, SFLLR or thrombin, each at a saturating dose, re-
sulted in an elevated positive DMR that prolongs for at least 2 h
when the cells were continuously exposed to the agonists under
static or perfusion condition (Fig. 3a). However, the thrombin
DMR was not altered by removal of thrombin 30 min after stimu-
lation (Fig. 3b). Conversely, removal of SFLLR 30 min after stimula-
tion rapidly reversed the course of its DMR back to a much lower
level (Fig. 3b). This suggests that certain signaling pathways in-
duced by SFLLR require persistent agonist occupancy.
Finally, we examined the mechanisms of PAR1 resensitization.
Here, cells were pre-exposed to cycloheximide for about 1 h, fol-
lowed by stimulation with thrombin in the presence of cyclohexi-
mide for 30 min. Afterwards, the ﬁrst thrombin was removed, andthe cells were perfused with cycloheximide for 30 min. Finally, the
cells were then stimulated again with the second PAR1 agonist,
SFLLR or thrombin. Cycloheximide is an inhibitor of protein biosyn-
thesis via interfering with the translocation step in protein synthe-
sis [23]. Results showed that the presence of cycloheximide altered
the characteristics of the ﬁrst thrombin induced DMR signals
(Fig. 4 vs Figs. 2 and 3b). Further, when the recovery time was
set to be 30 min and cycloheximide was present throughout the as-
say, the thrombin activated cells completely lost their responsive-
ness to the succeeding thrombin stimulation, but regained their
responsiveness to SFLLR (Fig. 4). These results suggest that persis-
tent PAR1 signaling requires de novo synthesis and receptor cycling
back to cell membrane.
4. Discussion
Elucidation of ligand-directed receptor trafﬁcking and signal
termination is important to understand biological functions of
the PAR1 and therapeutic potentials of PAR1 ligands. Here, we de-
scribed a microﬂuidic RWG biosensor system which enables la-
bel-free cellular assays under the control of the duration of
agonist exposure and of the functional recovery of activated recep-
tors. Endogenous PAR1 in A549 was used as a model system. Quan-
titative RT-PCR showed that A549 cells express mRNAs of PAR1,
PAR2 and PAR3, but not PAR4. Further, DMR assays revealed that
the PAR1 is functional – both thrombin and SFLLR resulted in ro-
bust DMR signals, and cross-desensitized each other under the per-
sistent stimulation conditions.
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PAR1 signaling. First, the functional recovery of activated PAR1 in-
duced by thrombin is much slower than that by SFLLR (Fig. 3d).
This difference is attributed to the distinct abilities of the two ago-
nists to cause receptor trafﬁcking. Since SFLLR is known to cause
receptor phosphorylation and internalization to an extent similar
to thrombin [24,25], one possibility is that SFLLR has lower efﬁ-
ciency to result in the internalized receptors sorting into lysosomes
for degradation, compared to thrombin. Lysosomal sorting is nec-
essary to prevent persistent signaling by activated PAR1 [26–28].
Second, the thrombin-activated cells completely lost their
responsiveness to the succeeding stimulation with thrombin, but
not SFLLR, when the cells were continuously exposed to cyclohex-
imide and the recovery time was set to be 30 min. This is consis-
tent with previous reports that in some cells a steady-state level
of cleaved receptors was detected on the cell surface after pro-
longed stimulation with thrombin [29,30]. In such a state, cells
were refractory to thrombin but responded to SFLLRN. Interest-
ingly, the presence of cycloheximide altered the thrombin DMR
signal. It is known that PAR1 is cycled tonically between an intra-
cellular pool and cell surface membrane [31,32]; thus, it is possible
that the intracellular receptor pool become less in the absence of
protein synthesis via blockage by cycloheximide, and the persis-
tent activation of PAR1 by thrombin can quickly deplete the intra-
cellular pool, leading to alterations in the thrombin DMR.
Lastly, thrombin triggered an elevated DMR that prolongs for at
least 2 h, which was largely insensitive to thrombin removal. How-
ever, the SFLLR DMR quickly reversed its course after SFLLR re-
moval. Given the integrative nature and dependence on protein
trafﬁcking and redistribution of DMR measurements [15–17], the
reversibility of the SFLLR DMR after agonist removal is a surprise
ﬁnding. It is believed that 30 min after agonist activation many
GPCR signaling events are completed, or have already propagated
[33]. Although a recent study suggests that removal of agonists in-
deed caused dissociation of b-arrestin from the phosphorylated b2-
adrenergic receptor [34], there is no any reports suggesting that
agonist removal can rapidly reverse cell signaling pathway(s)
downstream receptor activation. The molecular mechanisms
underneath are currently under investigation.
In summary, we have developed a microﬂuidic RWG biosensor
system for whole cell sensing. Using PAR1 as a model, we have
shown that such a system allows the control of the duration of ago-
nist exposure as well as of the functional recovery of activated
receptors, such that ligand-directed receptor trafﬁcking and signal
termination between thrombin and SFLLR can be differentiated.
Further deconvoluting the cellular mechanisms underneath thefunctional difference between thrombin and PAR-APs, such as the
ability of PAR-APs to trigger receptor degradation and the role of
PAR3 in regulating PAR1 signaling [35], would be beneﬁcial to
understanding the biology and therapeutic potential of PARs. The
microﬂuidic RWG biosensor system offers a new dimension in
sensing ligand-directed functional selectivity acting on GPCRs.References
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